Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) posted its earnings results on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, Zacks reports.
Scinai Immunotherapeutics Price Performance
Shares of Scinai Immunotherapeutics stock opened at $3.22 on Monday. The business has a 50 day simple moving average of $2.67 and a two-hundred day simple moving average of $5.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.35 and a quick ratio of 1.35. The stock has a market capitalization of $1.67 million, a P/E ratio of -3.04 and a beta of 2.08. Scinai Immunotherapeutics has a 12 month low of $2.15 and a 12 month high of $17.20.
Institutional Trading of Scinai Immunotherapeutics
A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC increased its holdings in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. Institutional investors and hedge funds own 58.41% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Scinai Immunotherapeutics
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.
Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.
See Also
- Five stocks we like better than Scinai Immunotherapeutics
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
